Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 5

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 5
---
 - B Execution, Exploration of Development, Pipeline and Capital Returns 2019 and Prior 2020 - 2022 2023 Onward Dynavax Successfully Pivoted from a Struggling Biotech with an Immuno - Oncology Business … Source: Market data as of the filing date of our definitive proxy statement, 17 - Apr - 2025 1 Total stockholder return from 23 - May - 19, the date that DVAX announced its strategic pivot , to 17 - Apr - 2025, the date of Dynavax’s definitive proxy filing . 2 Based on net HEPLISAV - B revenues, not quantity of doses administered. 1 23 - May - 19 Announced strategic refocus on vaccine business / HEPLISAV - B, and strategic alternatives for I - O portfolio 16 - Dec - 19 Appointed Ryan Spen c er as CEO 01 - Mar - 21 Appointed Kelly MacDonald as CFO 08 - Jan - 24 Achieved first full quarter of HEPLISAV - B profitability 22 - Feb - 24 HEPLISAV - B achieved #1 market share for first full year (42% in FY23) 2 21 - Oct - 21 Appointed Scott Myers as Board Chairman 04 - Aug - 22 Reported record earnings inc l. $223M in CpG sales (+471% YoY) and $33M in HEPLISAV - B sales (+139% YoY) 17 - Apr - 25 Dynava x f iled definitive proxy Apr - 2025 Stock Price Performance $ 6.35 (100)% (50)% 0 % 50 % 100 % 150 % 200 % 250 % May-2019 May-2020 May-2021 May-2022 May-2023 May-2024 $ 10.31 62.4 % (7.2)% S&P Biotechnology Select Industry Index (XBI)

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx HEPLISAV - B Has Quickly Overtaken Incumbent Market Leader GSK’s ENGERIX - B Vaccine 2 Doses in 1 Month x v s. 3 doses in